A
ASCENDIS PHARMA AS
NASDAQ: ASND (Ascendis Pharma A/S)
Last update: 9 hours ago172.06
4.59 (2.74%)
| Previous Close | 167.47 |
| Open | 167.84 |
| Volume | 1,175,394 |
| Avg. Volume (3M) | 543,186 |
| Market Cap | 10,387,864,576 |
| Price / Sales | 24.18 |
| 52 Weeks Range | |
| Earnings Date | 1 May 2025 |
| Profit Margin | -92.67% |
| Operating Margin (TTM) | -103.23% |
| Diluted EPS (TTM) | -6.57 |
| Quarterly Revenue Growth (YOY) | 5.30% |
| Current Ratio (MRQ) | 1.04 |
| Operating Cash Flow (TTM) | -218.93 M |
| Levered Free Cash Flow (TTM) | -133.44 M |
| Return on Assets (TTM) | -22.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Ascendis Pharma A/S | Bullish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.78% |
| % Held by Institutions | 110.29% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 280.00 (Evercore ISI Group, 62.73%) | Buy |
| Median | 208.50 (21.18%) | |
| Low | 200.00 (JP Morgan, 16.24%) | Buy |
| 200.00 (Cantor Fitzgerald, 16.24%) | Buy | |
| Average | 220.33 (28.05%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 160.16 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 02 May 2025 | 280.00 (62.73%) | Buy | 172.06 |
| 18 Feb 2025 | 260.00 (51.11%) | Buy | 156.19 | |
| Wedbush | 02 May 2025 | 212.00 (23.21%) | Buy | 172.06 |
| RBC Capital | 16 Apr 2025 | 205.00 (19.14%) | Buy | 158.15 |
| JP Morgan | 18 Mar 2025 | 200.00 (16.24%) | Buy | 164.65 |
| 13 Feb 2025 | 168.00 (-2.36%) | Buy | 142.49 | |
| Cantor Fitzgerald | 25 Feb 2025 | 200.00 (16.24%) | Buy | 151.53 |
| 11 Feb 2025 | 170.00 (-1.20%) | Buy | 119.51 | |
| Goldman Sachs | 13 Feb 2025 | 225.00 (30.77%) | Buy | 142.49 |
| Date | Type | Details |
|---|---|---|
| 01 May 2025 | Announcement | Ascendis Pharma Reports First Quarter 2025 Financial Results |
| 24 Apr 2025 | Announcement | Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025 |
| 31 Mar 2025 | Announcement | Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia |
| 24 Feb 2025 | Announcement | Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference |
| 20 Feb 2025 | Announcement | FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA |
| 12 Feb 2025 | Announcement | Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs |
| 12 Feb 2025 | Announcement | Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results |
| 05 Feb 2025 | Announcement | Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |